Skip to main
  1. Stocks
  2. SAB Biotherapeutics
  3. Forecast
SABS

SAB Biotherapeutics (SABS) Stock Forecast & Price Target

SAB Biotherapeutics (SABS) Analyst Ratings

Based on 9 analyst ratings
Strong Buy
Strong Buy 78%
Buy 22%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

SAB Biotherapeutics is well positioned because FDA accelerated approval of Tzield in Stage 3 T1D validates C-peptide as an approvable surrogate endpoint, directly de-risking SAB-142’s ongoing SAFEGUARD trial, whose primary endpoint is stimulated C-peptide at 12 months. The company also appears differentiated on safety and dosing convenience: SAB-142 has shown low immunogenicity, no serum sickness, no neutropenia, and a repeat-dose profile that could support chronic use, while Tzield carries boxed-warning immune-related risks and a burdensome 14-day IV regimen. Fundamentally, the addressable opportunity remains large, with about 1.5 million people living with T1D in the U.S. and roughly 64,000 new cases per year, supporting meaningful upside if SAB-142 can capture even a modest share.

Bears say

SAB Biotherapeutics is a clinical-stage biotech with a history of losses, and the company expects significant operating deficits to continue as it funds research, preclinical work, and clinical development, making profitability uncertain. Its investment case is highly concentrated in SAB-142, while limited human clinical data, regulatory uncertainty with the FDA and EMA, and the risk of not meeting safety or efficacy endpoints create a binary outcome profile that could materially impair value. Financial risk is compounded by the need for future debt or equity financing, possible dilution, a herd-dependent manufacturing model with about 200 genetically engineered production animals in South Dakota, and intense competition from better-resourced rivals and existing products.

SAB Biotherapeutics (SABS) has been analyzed by 9 analysts, with a consensus rating of Strong Buy. 78% of analysts recommend a Strong Buy, 22% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of SAB Biotherapeutics and is not a guaranteed prediction by Public.com or investment advice.

SAB Biotherapeutics (SABS) Analyst Forecast & Price Prediction

Get the latest SAB Biotherapeutics (SABS) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in SAB Biotherapeutics (SABS)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About SAB Biotherapeutics (SABS) Forecast

Analysts have given SAB Biotherapeutics (SABS) a Strong Buy based on their latest research and market trends.

According to 9 analysts, SAB Biotherapeutics (SABS) has a Strong Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

SAB Biotherapeutics (SABS)


SAB Biotherapeutics (SABS) Analyst Forecast & Price Prediction

Get the latest SAB Biotherapeutics (SABS) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in SAB Biotherapeutics (SABS)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover SABS stock data and trends